|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 2 (January 15), 2000:
pp. 619-626
Increased proteasome degradation of cyclin-dependent kinase
inhibitor p27 is associated with a decreased overall survival in
mantle cell lymphoma
Roberto Chiarle,
Leo M. Budel,
Jeffrey Skolnik,
Glauco Frizzera,
Marco Chilosi,
Alessandra Corato,
Gianni Pizzolo,
Jory Magidson,
Alessia Montagnoli,
Michele Pagano,
Brigitte Maes,
Christine De Wolf-Peeters, and
Giorgio Inghirami
From the Department of Pathology and the Kaplan Comprehensive Cancer
Center, New York University School of Medicine; the Institute of
Pathology, Erasmus University of Rotterdam, the Netherlands; the
Department of Pathological Anatomy and Histology and the Department of
Medicine, University of Verona, Italy, the Department of Pathology,
Morristown Memorial Hospital, NJ; and the Department of
Surgical Pathology, University of Leuven, Belgium.
Mantle cell lymphoma (MCL) is an aggressive neoplasm characterized
by the deregulated expression of cyclin D1 by t(11;14). The molecular
mechanisms responsible for MCL's clinical behavior remain unclear. The
authors have investigated the expression of p53, E2F-1, and the CDK
inhibitors p27 and p21 in 110 MCLs, relating their expression to
proliferative activity (Ki-67). For comparison, they have similarly
analyzed low-grade (12 MALT, 16 CLL/SLL) and high-grade (19 DLCL)
lymphomas. p53 was detected more frequently in large-cell MCL
(l-MCL; 5 of 7) than in classical MCL (s-MCL; 13 of 103) and DLCL (8 of
19). In MCL and DLCL, the percentage of E2F-1+ nuclei was high,
correlating with high Ki-67 expression. Most MCLs (91 of 112) and DLCLs
(12 of 19) showed a loss of p27; MALT and CLL/SLL, however, were p27
positive. Reverse transcription-polymerase chain reaction and in vitro
protein degradation assays demonstrated that MCLs have normal p27 mRNA
expression but increased p27 protein degradation activity via the
proteasome pathway. Correlation of MCL p53 and p27 expression with
clinical data showed an association between reduced overall survival
rates and the overexpression of p53 (P = .001), the loss of
p27 (P = .002), or both. Loss of p27 identified patients
with a worse clinical outcome among p53 negative cases
(P = .002). These findings demonstrated that MCL has a
distinct cell cycle protein expression similar to that of high-grade
lymphoma. The loss of p27 and the overexpression of p53 in MCL are
prognostic markers that identify patients at high risk. The
demonstration that low levels of p27 in MCL result from enhanced
proteasome-mediated degradation should encourage additional clinical
trials. (Blood. 2000;95:619-626)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. YABUUCHI, Y. KATAYOSE, A. ODA, M. MIZUMA, S. SHIRASOU, T. SASAKI, K. YAMAMOTO, M. OIKAWA, T. RIKIYAMA, T. ONOGAWA, et al.
ZD1839 (IRESSA(R)) Stabilizes p27Kip1 and Enhances Radiosensitivity in Cholangiocarcinoma Cell Lines
Anticancer Res,
April 1, 2009;
29(4):
1169 - 1180.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Voorhees, E C. Dees, B. O'Neil, and R. Z Orlowski
The Proteasome as a Target for Cancer Therapy
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
153 - 170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kim, J. M. Brush, P. A. Watson, N. A. Cacalano, K. S. Iwamoto, and W. H. McBride
Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation
Mol. Cancer Res.,
March 1, 2008;
6(3):
426 - 434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Kienle, T. Katzenberger, G. Ott, D. Saupe, A. Benner, H. Kohlhammer, T. F.E. Barth, S. Holler, J. Kalla, A. Rosenwald, et al.
Quantitative Gene Expression Deregulation in Mantle-Cell Lymphoma: Correlation With Clinical and Biologic Factors
J. Clin. Oncol.,
July 1, 2007;
25(19):
2770 - 2777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. O'Connor
Mantle Cell Lymphoma: Identifying Novel Molecular Targets in Growth and Survival Pathways
Hematology,
January 1, 2007;
2007(1):
270 - 276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, S. H. Bernstein, B. S. Kahl, B. Djulbegovic, M. J. Robertson, S. de Vos, E. Epner, A. Krishnan, J. P. Leonard, S. Lonial, et al.
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
J. Clin. Oncol.,
October 20, 2006;
24(30):
4867 - 4874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hulit, R. J. Lee, Z. Li, C. Wang, S. Katiyar, J. Yang, A. A. Quong, K. Wu, C. Albanese, R. Russell, et al.
p27Kip1 Repression of ErbB2-Induced Mammary Tumor Growth in Transgenic Mice Involves Skp2 and Wnt/{beta}-Catenin Signaling.
Cancer Res.,
September 1, 2006;
66(17):
8529 - 8541.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Fu, D. D. Weisenburger, T. C. Greiner, S. Dave, G. Wright, A. Rosenwald, M. Chiorazzi, J. Iqbal, S. Gesk, R. Siebert, et al.
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling
Blood,
December 15, 2005;
106(13):
4315 - 4321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hachem and R. B. Gartenhaus
Oncogenes as molecular targets in lymphoma
Blood,
September 15, 2005;
106(6):
1911 - 1923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Fernandez, E. Hartmann, G. Ott, E. Campo, and A. Rosenwald
Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways
J. Clin. Oncol.,
September 10, 2005;
23(26):
6364 - 6369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. A. O'Connor
Targeting Histones and Proteasomes: New Strategies for the Treatment of Lymphoma
J. Clin. Oncol.,
September 10, 2005;
23(26):
6429 - 6436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.L. Hamilton, J.P. Eder, A.C. Pavlick, J.W. Clark, L. Liebes, R. Garcia-Carbonero, A. Chachoua, D.P. Ryan, V. Soma, K. Farrell, et al.
Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
J. Clin. Oncol.,
September 1, 2005;
23(25):
6107 - 6116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mani and E. P. Gelmann
The Ubiquitin-Proteasome Pathway and Its Role in Cancer
J. Clin. Oncol.,
July 20, 2005;
23(21):
4776 - 4789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-H. Jeon, K.-N. Lee, C. Y. Hwang, K.-S. Kwon, K.-H. You, and I. Choi
Tumor Suppressor VDUP1 Increases p27kip1 Stability by Inhibiting JAB1
Cancer Res.,
June 1, 2005;
65(11):
4485 - 4489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Kienle, C. Korz, B. Hosch, A. Benner, D. Mertens, A. Habermann, A. Krober, U. Jager, P. Lichter, H. Dohner, et al.
Evidence for Distinct Pathomechanisms in Genetic Subgroups of Chronic Lymphocytic Leukemia Revealed by Quantitative Expression Analysis of Cell Cycle, Activation, and Apoptosis-Associated Genes
J. Clin. Oncol.,
June 1, 2005;
23(16):
3780 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kudo, S. Kitajima, I. Ogawa, M. Kitagawa, M. Miyauchi, and T. Takata
Small interfering RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation
Mol. Cancer Ther.,
March 1, 2005;
4(3):
471 - 476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Sheng, G. Wang, Y. Wang, J. Liang, J. Wen, P.-S. Zheng, Y. Wu, V. Lee, J. Slingerland, D. Dumont, et al.
The Roles of Versican V1 and V2 Isoforms in Cell Proliferation and Apoptosis
Mol. Biol. Cell,
March 1, 2005;
16(3):
1330 - 1340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kitajima, Y. Kudo, I. Ogawa, T. Bashir, M. Kitagawa, M. Miyauchi, M. Pagano, and T. Takata
Role of Cks1 Overexpression in Oral Squamous Cell Carcinomas: Cooperation with Skp2 in Promoting p27 Degradation
Am. J. Pathol.,
December 1, 2004;
165(6):
2147 - 2155.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bezombes, S. Grazide, C. Garret, C. Fabre, A. Quillet-Mary, S. Muller, J.-P. Jaffrezou, and G. Laurent
Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains
Blood,
August 15, 2004;
104(4):
1166 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Min, J.-W. Cheong, J. Y. Kim, J. I. Eom, S. T. Lee, J. S. Hahn, Y. W. Ko, and M. H. Lee
Cytoplasmic Mislocalization of p27Kip1 Protein Is Associated with Constitutive Phosphorylation of Akt or Protein Kinase B and Poor Prognosis in Acute Myelogenous Leukemia
Cancer Res.,
August 1, 2004;
64(15):
5225 - 5231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Min, J.-W. Cheong, M. H. Lee, J. Y. Kim, S. T. Lee, J. S. Hahn, and Y. W. Ko
Elevated S-Phase Kinase-Associated Protein 2 Protein Expression in Acute Myelogenous Leukemia: Its Association with Constitutive Phosphorylation of Phosphatase and Tensin Homologue Protein and Poor Prognosis
Clin. Cancer Res.,
August 1, 2004;
10(15):
5123 - 5130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kohlhammer, C. Schwaenen, S. Wessendorf, K. Holzmann, H. A. Kestler, D. Kienle, T. F. E. Barth, P. Moller, G. Ott, J. Kalla, et al.
Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions
Blood,
August 1, 2004;
104(3):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. Fisher, T. P. Miller, and O. A. O'Connor
Diffuse Aggressive Lymphoma
Hematology,
January 1, 2004;
2004(1):
221 - 236.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diez-Juan, P. Perez, M. Aracil, D. Sancho, A. Bernad, F. Sanchez-Madrid, and V. Andres
Selective inactivation of p27Kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis
Blood,
January 1, 2004;
103(1):
158 - 161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Voorhees, E. C. Dees, B. O'Neil, and R. Z. Orlowski
The Proteasome as a Target for Cancer Therapy
Clin. Cancer Res.,
December 15, 2003;
9(17):
6316 - 6325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Pham, A. T. Tamayo, L. C. Yoshimura, P. Lo, and R. J. Ford
Inhibition of Constitutive NF-{kappa}B Activation in Mantle Cell Lymphoma B Cells Leads to Induction of Cell Cycle Arrest and Apoptosis
J. Immunol.,
July 1, 2003;
171(1):
88 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Drobnjak, J. Melamed, S. Taneja, K. Melzer, R. Wieczorek, B. Levinson, A. Zeleniuch-Jacquotte, D. Polsky, J. Ferrara, R. Perez-Soler, et al.
Altered Expression of p27 and Skp2 Proteins in Prostate Cancer of African-American Patients
Clin. Cancer Res.,
July 1, 2003;
9(7):
2613 - 2619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Payne and C. J. Kemp
p27 Kip1 (Cdkn1b)-Deficient Mice Are Susceptible to Chemical Carcinogenesis and May Be a Useful Model for Carcinogen Screening
Toxicol Pathol,
June 1, 2003;
31(4):
355 - 363.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Quintanilla-Martinez, T. Davies-Hill, F. Fend, J. Calzada-Wack, L. Sorbara, E. Campo, E. S. Jaffe, and M. Raffeld
Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis
Blood,
April 15, 2003;
101(8):
3181 - 3187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.-H. Shim, L. Johnson, H.-L. Noh, Y.-J. Kim, H. Sun, C. Zeiss, and H. Zhang
Expression of the F-Box Protein SKP2 Induces Hyperplasia, Dysplasia, and Low-Grade Carcinoma in the Mouse Prostate
Cancer Res.,
April 1, 2003;
63(7):
1583 - 1588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Z. Rassidakis, F.-X. Claret, R. Lai, Q. Zhang, A. H. Sarris, T. J. McDonnell, and L. J. Medeiros
Expression of p27Kip1 and c-Jun Activation Binding Protein 1 Are Inversely Correlated in Systemic Anaplastic Large Cell Lymphoma
Clin. Cancer Res.,
March 1, 2003;
9(3):
1121 - 1128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chiarle, J. Z. Gong, I. Guasparri, A. Pesci, J. Cai, J. Liu, W. J. Simmons, G. Dhall, J. Howes, R. Piva, et al.
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
Blood,
March 1, 2003;
101(5):
1919 - 1927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood,
February 15, 2003;
101(4):
1220 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Filipits, G. Pohl, T. Stranzl, H. Kaufmann, J. Ackermann, H. Gisslinger, H. Greinix, A. Chott, and J. Drach
Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma
Clin. Cancer Res.,
February 1, 2003;
9(2):
820 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Lim, A. Adamson, Z. Lin, B. Perez-Ordonez, R. C. K. Jordan, S. Tripp, S. L. Perkins, and K. S. J. Elenitoba-Johnson
Expression of Skp2, a p27Kip1 ubiquitin ligase, in malignant lymphoma: correlation with p27Kip1 and proliferation index
Blood,
September 26, 2002;
100(8):
2950 - 2956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Korz, A. Pscherer, A. Benner, D. Mertens, C. Schaffner, E. Leupolt, H. Dohner, S. Stilgenbauer, and P. Lichter
Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes
Blood,
May 29, 2002;
99(12):
4554 - 4561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chiarle, Y. Fan, R. Piva, H. Boggino, J. Skolnik, D. Novero, G. Palestro, C. De Wolf-Peeters, M. Chilosi, M. Pagano, et al.
S-Phase Kinase-Associated Protein 2 Expression in Non-Hodgkin's Lymphoma Inversely Correlates with p27 Expression and Defines Cells in S Phase
Am. J. Pathol.,
April 1, 2002;
160(4):
1457 - 1466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Carrano and M. Pagano
Role of the F-Box Protein Skp2 in Adhesion-Dependent Cell Cycle Progression
J. Cell Biol.,
June 25, 2001;
153(7):
1381 - 1390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Waltregny, I. Leav, S. Signoretti, P. Soung, D. Lin, F. Merk, J. Y. Adams, N. Bhattacharya, N. Cirenei, and M. Loda
Androgen-Driven Prostate Epithelial Cell Proliferation and Differentiation in Vivo Involve the Regulation of p27
Mol. Endocrinol.,
May 1, 2001;
15(5):
765 - 782.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. Latres, R. Chiarle, B. A. Schulman, N. P. Pavletich, A. Pellicer, G. Inghirami, and M. Pagano
Role of the F-box protein Skp2 in lymphomagenesis
PNAS,
February 15, 2001;
(2001)
41475098.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology,
January 1, 2001;
2001(1):
443 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Latres, R. Chiarle, B. A. Schulman, N. P. Pavletich, A. Pellicer, G. Inghirami, and M. Pagano
Role of the F-box protein Skp2 in lymphomagenesis
PNAS,
February 27, 2001;
98(5):
2515 - 2520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
